Towards depersonalized abacavir therapy
- 28 November 2015
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 29 (18) , 2385-2395
Abstract
Exposure to abacavir is associated with T-cell-mediated hypersensitivity reactions in individuals carrying human leukocyte antigen (HLA)-B*57 : 01. To activate T cells, abacavir interacts directly with endogenous HLA-B*57 : 01 and HLA-B*57 : 01 expressed on the surface of antigen presenting cells. We have investigated whether chemical modification of abacavir can produce a molecule with antiviral activity that does not bind to HLA-B*57 : 01 and activate T cells. An interdisciplinary laboratory study using samples from human donors expressing HLA-B*57 : 01. Researchers were blinded to the analogue structures and modelling data. Sixteen 6-amino substituted abacavir analogues were synthesized. Computational docking studies were completed to predict capacity for analogue binding within HLA-B*57 : 01. Abacavir-responsive CD8+ clones were generated to study the association between HLA-B*57 : 01 analogue binding and T-cell activation. Antiviral activity and the direct inhibitory effect of analogues on proliferation were assessed. Major histocompatibility complex class I-restricted CD8+ clones proliferated and secreted IFNγ following abacavir binding to surface and endogenous HLA-B*57 : 01. Several analogues retained antiviral activity and showed no overt inhibitory effect on proliferation, but displayed highly divergent antigen-driven T-cell responses. For example, abacavir and N-propyl abacavir were equally potent at activating clones, whereas the closely related analogues N-isopropyl and N-methyl isopropyl abacavir were devoid of T-cell activity. Docking abacavir analogues to HLA-B*57 : 01 revealed a quantitative relationship between drug–protein binding and the T-cell response. These studies demonstrate that the unwanted T-cell activity of abacavir can be eliminated whilst maintaining the favourable antiviral profile. The in-silico model provides a tool to aid the design of safer antiviral agents that may not require a personalized medicines approach to therapy.Keywords
This publication has 27 references indexed in Scilit:
- Abacavir induces loading of novel self-peptides into HLA-B*57AIDS, 2012
- Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoireProceedings of the National Academy of Sciences, 2012
- Drug hypersensitivity: Pharmacogenetics and clinical syndromesJournal of Allergy and Clinical Immunology, 2011
- HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinNature Genetics, 2009
- Human Leukocyte Antigen Class I-Restricted Activation of CD8+ T Cells Provides the Immunogenetic Basis of a Systemic Drug HypersensitivityImmunity, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- A Review of the Pharmacokinetics of AbacavirClinical Pharmacokinetics, 2008
- In Vitro Synergy and Enhanced Murine Brain Penetration of Saquinavir Coadministered with MefloquineThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4Journal of Virology, 2004
- A marker for Stevens–Johnson syndromeNature, 2004